Immunology

Antibody-cytokine fusion proteins are a promising immunotherapy that could overcome off-target immune cell activation and the short serum half-life associated with low-dose interleukin-2 treatment. We were delighted to talk with Dr. Jamie Spangler (Johns Hopkins University, Baltimore, MD, USA) around the rationale for fusing cytokines to anti-cytokine antibodies in targeted therapy, the improved therapeutic efficacy […]

Prof. Tobias Derfuss reviews the cellular model of disease in multiple sclerosis, and how pathophysiology can offer novel therapeutic targets.

Welcome to the latest issue of touchREVIEWS in RMD, which aims to provide healthcare professionals with a wide range of topical articles in the field of rheumatic and musculoskeletal disorders. We begin with an expert interview in which Victoria Furer describes a study on the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination […]

Watch three experts discuss the pathophysiology of cold agglutinin disease (CAD) and the steps needed for an accurate diagnosis. The panel goes on to discuss how emerging treatment options are changing the management of patients with primary CAD and the importance of tailoring treatment to improve outcomes. The discussion is guided by pre-canvassed questions provided by the haematological clinical community.

Watch experts give their perspective on different aspects of managing patients with EoE, based on clinical case studies.

Watch leading experts discuss practical aspects of caring for children and adults with EoE, drawing on their own clinical experiences.

The ENABLE study (ClinicalTrials.gov Identifier: NCT04130191) is an observational study, investigating the effectiveness of lanadelumab in real-life use in patients with hereditary angioedema with C1 inhibitor deficiency (HAE-C1-1NH). touchIMMUNOLOGY were delighted to speak with Dr. Andreas Recke (University of Lübeck, Lübeck, Germany) to discuss the aims, design and findings from his interim analysis of the […]

Hereditary angioedema with C1-inhibitor deficiency (HAE-C1-INH) is a rare disease resulting in unpredictable attacks of swelling under the skin. touchIMMUNOLOGY were delighted to speak with Dr. Andreas Recke (University of Lübeck, Lübeck, Germany) around the health burden of HAE-C1-INH and the unmet needs in its treatment. The abstract ‘Lanadelumab Treatment Patterns Among Patients With HAE-C1-INH: Interim […]

Watch leading specialists involved in the multidisciplinary care of patients with eosinophilic oesophagitis address the optimal management of this disorder.